Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
Pipeline & Medicines
Product Pipeline & Portfolio
Theratechnologies develops and commercializes innovative therapies. The Company currently commercializes two products in the field of HIV. Trogarzo® and EGRIFTA SV® are approved in the United States. We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for nonalcoholic steatohepatitis (NASH), a severe liver condition which affects a growing number of people around the world.
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.